EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Portal vein thrombosis following targeted-release budesonide in IgA nephropathy and occult liver disease

Gerald S Braun iD, Claudia Seikrit iD

Clinical Kidney Journal · 02.11.2026 · 19 (11)

DOI: 10.1093/ckj/sfag372 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Kidney Journal, online erschienen am 22.10.2026. Verfasst von Gerald S Braun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Rheumatology, RWTH University Hospital, Aachen, Germany. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted-release budesonide (Nefecon) is the first gut–kidney axis-directed therapy for high-risk immunoglobulin A nephropathy (IgAN) and relies on intact hepatic first-pass metabolism to limit systemic exposure. We report a 63-year-old man who developed acute portal vein thrombosis within 3 days of treatment initiation. Imaging demonstrated near-complete thrombosis of the portal venous system. Subsequent evaluation revealed previously unrecognized chronic liver disease, including hereditary hemochromatosis, alcohol use, and early hepatocellular carcinoma without vascular invasion. In conjunction with three previously reported cases of splanchnic vein thrombosis in patients receiving budesonide to treat advanced autoimmune hepatobiliary disease and published pharmacokinetic data, this observation suggests that hepatic dysfunction and disease may lower the thrombotic threshold for budesonide. These findings support careful assessment of hepatic function when initiating targeted-release budesonide in IgAN.

Schlagwörter

Stichwörter der Autor:innen

IgA nephropathyNefeconbudesonidefirst-pass metabolismhepatic dysfunctionhepatocellular carcinoma adverse drug-reactionhereditary hemochromatosisportal vein thrombosis

Autor:innen und Institutionen

  • Department of Nephrology and Rheumatology, RWTH University Hospital, Aachen, Germany.
  • Department of Nephrology, Sana Klinikum Oberfranken, Coburg, Germany.
  • KfH Nierenzentrum, Coburg, Germany.
  • School of Medicine, University of Split, Split, Croatia.

ORCID-Profile: Gerald S Braun, Claudia Seikrit

Zitieren

APA

Braun, G. S., & Seikrit, C. (2026). Portal vein thrombosis following targeted-release budesonide in IgA nephropathy and occult liver disease. Clinical Kidney Journal, 19(11). https://doi.org/10.1093/ckj/sfag372

Vancouver

Braun GS, Seikrit C. Portal vein thrombosis following targeted-release budesonide in IgA nephropathy and occult liver disease. Clinical Kidney Journal. 2026;19(11). doi:10.1093/ckj/sfag372

BibTeX
@article{Braun2026,
  author = {Braun, Gerald S and Seikrit, Claudia},
  title = {Portal vein thrombosis following targeted-release budesonide in IgA nephropathy and occult liver disease},
  journal = {Clinical Kidney Journal},
  year = {2026},
  volume = {19},
  number = {11},
  doi = {10.1093/ckj/sfag372}
}
Kostenlos starten →